Endocrine Abstracts

BackgroundSodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce deaths and cardiovascular events in patients with type 2 diabetes mellitus (T2DM), but are currently not used as first-line therapy.ObjectiveTo evaluate the cost-effectiveness of introducing empagliflozin into the current standard care (metformin monotherapy) for patients with newly diagnosed T2DM and existing cardiovascular...

BackgroundSodium-glucose cotransporter 2 (SGLT2) inhibitors are potentially an attractive option for initial combination therapy with metformin for type 2 diabetes mellitus (T2DM), which may help patients to achieve adequate glycaemic control and reduce cardiovascular disease (CVD). Empagliflozin has been shown to be superior compared to other SGLT2 inhibitors in reducing all-cause and cardiovascular mortality in patients with T2DM.<p class="abstext"...